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Abstract. Serum cytokine profiles in patients with Plasmodium vivax malaria who presented with and without
hyperpyrexia were compared by a retrospective review of the medical records of the consecutive patients seen at the
military hospitals near the demilitarized zone in the Republic of Korea from April 2000 through October 2001. Of 162
male patients studied, 120 (86.4%) presented with hyperpyrexia (i.e., an axillary temperature 40°C). The mean ± SEM
ages of the patients with and without hyperpyrexia were 21.5 ± 0.14 and 21.9 ± 0.39 years, respectively (P 0.33). The
mean ± SEM concentrations of serum interleukin (IL)-6 (379.7 ± 44.1 pg/mL versus 105.4 ± 26.8 pg/mL; P  0.002),
IL-10 (583.4 ± 58.2 pg/mL versus 142.4 ± 39.7 pg/mL; P  0.0001), and interferon- (312.6 ± 33.9 pg/mL versus 112.9
± 27.1 pg/mL; P  0.0001) were significantly higher in patients with hyperpyrexia compared with those without
hyperpyrexia. The mean ± SEM concentrations of serum tumor necrosis factor- were 155.5 ± 54.5 pg/mL and 109.9 ±
29.3 pg/mL (P  0.27) in patients who presented with and without hyperpyrexia, respectively. Further studies are
needed to examine whether serum concentrations of these cytokines also parallel their concentrations at the tissue sites
of their production and action.
INTRODUCTION
As in many bacterial infections,1 hyperpyrexia is consid-
ered a hallmark of severe illness in malaria.2 However, the
factors responsible for the development of pyrexia in general
and hyperpyrexia in particular remain controversial.3 In fact,
the cause of pyrexia in malaria has been a matter of contro-
versy for many years.4 Unlike many gram-positive and gram-
negative organisms,5 no cell wall components of the malarial
parasite have been identified as being responsible for the de-
velopment of fever in malaria.3 Instead, the current consensus
on the pathogenesis of fever in malaria emphasizes the role of
various pro-inflammatory cytokines derived from host’s im-
mune cells that have been induced by as yet unknown para-
site-derived factors.6,7 Tumor necrosis factor- (TNF-) is
considered by some investigators8,9 as being central in the
pathogenesis of fever in malaria. Others have found a positive
correlation between the serum concentration of TNF- and
the degree of pyrexia in malaria.10,11 However, there is a
growing body of evidence to suggest that TNF- may not
necessarily be the most important pyrogenic cytokine in hu-
mans,12 and that TNF- may be responsible for the mainte-
nance, rather than the initiation, of pyrexia in proven micro-
bial infection.13 Therefore, we compared the cytokine profiles
of patients with Plasmodium vivax malaria who presented
with and without hyperpyrexia.
MATERIALS AND METHODS
The study population was composed of 162 consecutive
patients with P. vivax malaria seen at military hospitals in
Korea from April 2000 through October 2001. These were
military hospitals situated near the demilitarized zone (DMZ)
that marks the dividing line between South and North Korea.
The diagnosis of P. vivax malaria was established in all pa-
tients by the presence of pyrexia (i.e., axillary temperature
 37.0°C) and a positive malaria smear (i.e., one or more
asexual forms of P. vivax seen after microscopic examination
of 200 fields of Giemsa-stained thick (peripheral) blood films
at a magnification of ×1,000).
The study protocol was reviewed and approved by the Eth-
ics Committee and the Institutional Review Board of the par-
ticipating institutions. Informed consent of the patient was
not required due to retrospective nature of the study. All
subjects were identified on a data collection sheet by a study
number without any reference to their name and hospital
number.
Axillary temperature was recorded for all patients at pre-
sentation and very two hours thereafter during the course of
hospitalization. Laboratory investigations at presentations in-
cluded determination of the hemoglobin level, hematocrit,
total white blood cell (WBC) count, platelet count, and levels
of serum aspartate aminotransferase (AST) and alanine ami-
notransferase (ALT). Venous blood samples were also col-
lected for determining serum concentrations of interleukin
(IL)-1, IL-4, IL-6, IL-10, IL-12, TNF-, and interferon-
(IFN-).
For the cytokine assays, venous blood samples were drawn
aseptically into Vacutainer® tubes (Becton Dickinson and
Company, Franklin Lakes, NJ). Serum samples were sepa-
rated and aliquots were frozen at −70°C until assayed. In all
cases, tests to measure serum cytokine levels were run in
duplicate. The arithmetic mean of the results of both tests was
considered the final result. Commercially available specific
enzyme-linked immunosorbent assay kits (OptEIA™;
Pharmingen, San Diego, CA) were used for the cytokine as-
says according to the manufacturer’s instructions. For the
purpose of this study, hyperpyrexia was defined as an axillary
temperature  40.0°C.
Statistical analyses were done using the Wilcoxon rank sum
test without any assumption about the distribution of data.
Standard statistical software (SAS 6.12 version; SAS, Inc.,
Carey, NC) was used for all statistical analyses. Statistical
significance was defined as a P value < 0.05.
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RESULTS
The baseline characteristics of the study patients are shown
in Table 1. All were active duty military personnel from
within the catchment areas of Goyang, Paju, Yangju, Yeon-
cheon, and Cheolwon. All presented within 24 hours of the
onset of fever when they felt that they were still febrile. The
mean ± SEM of age of the patients who presented with hy-
perpyrexia was not significantly different from those who did
not (21.5 ± 0.14 years versus 21.9 ± 0.39 years; P  0.33).
There were no significant differences between the two patient
populations in terms of hemoglobin level (14.1 ± 0.12 g/dL
versus 13.6 ± 0.29 g/dL; P  0.73), hematocrit (40.4 ± 0.39%
versus 39.1 ± 0.94%; P 0.41), and platelet count (94.5 ± 3.8
× 109/L versus 104.9 ± 10.5 × 109/L; P 0.88). In contrast, the
hyperpyrexial patients presented with significantly lower
WBC counts compared with those without hyperpyrexia (5.2
± 0.34 × 109/L versus 6.4 ± 0.29 × 109/L; P  0.0001). The
mean ± SEM serum concentrations of ALT (50.9 ± 5.8 U/L
versus 44.9 ± 8.5 U/L; P 0.31), AST (45.2 ± 3.8 U/L versus
36.3 ± 4.3 U/L; P  0.09), IL-1 (127.8 ± 41.7 pg/mL versus
67.1 ± 23.9 pg/mL; P 0.96), IL-4 (91.4 pg/mL ± 25.6 versus
54.3 ± 18.3 pg/mL; P  0.38), IL-12 (258.7 ± 67.4 pg/mL
versus 393.6 ± 138.5 pg/mL; P  0.98), and TNF- (155.5 ±
54.5 pg/mL versus 109.9 ± 29.3 pg/mL; P  0.27) was not
significantly different in hyperpyrexial patients compared
with those who did not have hyperpyrexia. In contrast, pa-
tients with hyperpyrexia presented with significantly higher
concentrations of IL-6 (379.7 ± 44.1 pg/mL versus 105.4 ± 26.8
pg/mL; P 0.002), IL-10 (583.4 ± 58.2 pg/mL versus 142.4 ±
39.7 pg/mL; P  0.0001), and IFN- (312.6 pg/mL ± 33.9
versus 112.9 ± 27.1 pg/mL: P 0.0001) compared with those
without hyperpyrexia.
All patients received oral hydroxychloroquine sulfate (600-
mg base, followed by an additional 300-mg base after six
hours, and then 300-mg base again on days 2 and 3), followed
by oral primaquine phosphate (15-mg base per day orally for
two weeks). After discharge from the hospital, no patient
included was followed-up for relapse.
DISCUSSION
The purpose of this study was to compare serum cytokine
profiles of patients with P. vivax malaria presenting with and
without hyperpyrexia. The data presented herein show that as
group, the patients who presented with hyperpyrexia had sig-
nificantly higher serum concentrations of IL-6, IL-10, and
IFN- compared with those who did not present with hyper-
pyrexia. However, there was no significant difference be-
tween these two patient populations in terms of serum con-
centrations of other the cytokines tested (Table 1). Our data
do not support the contention that in P. vivax malaria there is
a positive association between the degree of pyrexia and con-
centration of TNF- in serum.10,11,14 The study design pre-
cluded us from determining whether the two patient popula-
tions differed in terms of TNF- concentrations at the site of
its production and action. However, this is highly pertinent
for several reasons. First, TNF- and other cytokines are ca-
pable of mediating critical cellular responses when present in
tissues at concentrations that are far lower than their concen-
trations in serum.15 Second, production of cytokines at the
tissue level is considered by many to be more important than
their production in the blood for the induction of signals lead-
ing to the development of fever.12 Third, up to what extent
cytokines, including TNF-, which are large hydrophilic pep-
tides cross the brain-blood barrier to act on the hypothalamic
thermo-regulatory region is not clear.16 Finally, the concen-
trations of serum TNF-, as measured immunologically in the
study subjects, may not be representative of the concentra-
tions of the biologically active (i.e., fraction unbound with
TNF- receptors) fraction of TNF-.3
Compared with those presenting without hyperpyrexia, hy-
perpyrexial patients presented with significantly higher serum
concentrations of IL-6 and IFN-. Brown and others17 have
also found a positive association between the serum concen-
tration of IFN- and degree of pyrexia in patients with P.
vivax malaria. However, significantly higher serum concen-
trations of IFN- found in the hyperpyrexial compared with
non-hyperpyrexial patients studied herein is somewhat baf-
fling. This is because IFN-, unlike IL-6,18 may not be intrin-
sically pyrogenic, and the pyrogenic properties of IFN- are
mediated through the induction of IL-1 and TNF-.19 This
makes it questionable whether the differences in serum con-
centrations of IFN-, as noted in this cohort study, could
explain the differences in their mean presenting temperatures
(Table 1), since the serum concentrations of IL-1 or TNF- at
presentation were not significantly different between hyper-
pyrexial and non-hyperpyrexial patients. Serum concentra-
tions of IL-10 were significantly higher in hyperpyrexial pa-
tients compared with those without hyperpyrexia. This is not
unexpected because stronger pro-inflammatory cytokine re-
sponses, as shown by the significantly higher serum concen-
trations of IL-6 and IFN- in hyperpyrexial patients, are ex-
pected to be balanced by a strong anti-inflammatory cytokine
response.20
At presentation, the total WBC count was significantly
higher in non-hyperpyrexial patients compared with that ob-
served in patients with hyperpyrexia. The reasons for this
TABLE 1






(n  42) P
Age (years) 21.5 ± 0.14 21.9 ± 0.39 0.33
Axillary temperature
(°C) 40.2 ± 0.06 37.5 ± 0.12 <0.001
WBC count (×109/L) 5.2 ± 0.34 6.4 ± 0.32 0.0001
Hemoglobin (g/dL) 14.1 ± 0.12‡ 13.6 ± 0.29 0.73
Hematocrit (%) 40.4 ± 0.39‡ 39.1 ± 0.94 0.41
Platelet count (×109/L) 94.5 ± 3.8‡ 104.9 ± 10.5 0.88
Serum ALT (U/L) 50.9 ± 5.8§ 44.9 ± 8.5‡ 0.31
Serum AST (U/L) 45.2 ± 3.8‡ 36.3 ± 4.3‡ 0.09
Serum IL-1 (pg/mL) 127.8 ± 41.7 67.1 ± 23.9 0.96
Serum IL-4 (pg/mL) 91.4 ± 25.6 54.3 ± 18.3 0.38
Serum IL-6 (pg/mL) 379.7 ± 44.1 105.4 ± 26.8 0.002
Serum IL-10 (pg/mL) 583.4 ± 58.2 142.4 ± 39.7 0.0001
Serum IL-12 (pg/mL) 258.7 ± 67.4 393.6 ± 138.5 0.98
Serum TNF- (pg/mL) 155.5 ± 54.5 109.9 ± 29.3 0.27
Serum IFN- (pg/mL) 312.6 ± 33.9 112.9 ± 27.1 0.0001
* Values are the mean ± SEM. WBC  white blood cell; ALT  alanine aminotrans-
ferase; AST  aspartate aminotransferase; IL  interleukin; TNF-  tumor necrosis
factor-; IFN- interferon-. Normal values: WBC count 4.0–11.0 × 109/L; hemoglobin
 11.5–13.5 g/dL; hematocrit  39.0–45.0%; platelet count  150.0–450.0 × 109/L; serum
ALT  10.0–40.0 units/L; serum AST  10.0–42.0 units/L.
† Defined as an axillary temperature  40°C.
‡ Data not available for one patient.
§ Data not available for two patients.
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remain unclear. Although IL-1 can cause an increase in the
peripheral blood leukocyte count by mobilizing leukocytes
from bone marrow,21 IL-6 can do this by mobilizing and de-
marginating leukocytes from bone marrow and intravascular
pool, respectively.22 In this study, there was no significant
difference between the study cohorts in terms of the serum
concentration of IL-1 at presentation. Furthermore, serum
IL-6 concentrations were significantly higher in hyperpyrexial
group compared with those without hyperpyrexia. These
again raises the possibility that these two patient populations
differed in terms of concentrations of IL-1 and IL-6 at the
sites of their action in bone marrow, vascular endothelia, or
both.
The level of parasite density was not determined in any
patient studied herein. However, it is more likely3,23 that the
levels of parasite density would be higher in patients with
hyperpyrexia than those without hyperpyrexia. Although
cases of minimally symptomatic P. vivax malaria with high
levels of parasitic density, presumably due to immune toler-
ance resulting from repeated exposures,10 have been reported
from areas hyperendemic for malaria,24 this is unlikely to be
the case in our patients. This is because malaria is not hyper-
endemic in the DMZ.25 No patient in this study had a history
of a diagnosis of malaria by a physician. All patients were
repeatedly asked about this during the course of hospitaliza-
tion. Furthermore, all study subjects repeatedly denied having
been treated for malaria at any time prior to the current
illness that prompted them to seek medical attention. Al-
though nutritional status may be relevant in the host’s febrile
response to infection,26 it is considered unlikely that any dif-
ference in nutritional status between the study cohorts could
explain the differences in their presenting temperature (Table
1) because they all were active duty military personnel with a
standard diet. In all patients studied, the possibility of other
causes of fever was excluded clinically by the physicians re-
sponsible for caring the patients. No patient received any
antimicrobial agent other than those mentioned earlier. Since
all study subjects were males, a practical implication of this is
that it excludes the possibility of any sex-related difference in
the host’s febrile response27 in infection and level of malarial
parasitemia.28
A study conducted in Sri Lanka has conveniently examined
serum levels of TNF during paroxysm in individual patients
infected with P. vivax.8 However, this study has addressed
only one aspect of the febrile responses seen in P. vivax ma-
laria, since many patients with P. vivax malaria, though fe-
brile, do not develop paroxysm at any stage during the course
of their illness.29,30 More importantly, individual patients may
differ in their sensitivity to a given amount of TNF.31 Fur-
thermore, the amount of TNF produced by patients with ma-
laria may vary among individuals residing in the same area
who have been exposed to similar parasites and with inocu-
lation rates.32
Several studies7,10,33,34 have examined serum cytokine pro-
files in patients with P. vivax malaria. However, the findings
of these studies, in comparison with those of our study, are
tempered with methodologic limitations. First, these studies
included subjects who had previously experienced malarial
attacks. These subjects were included, despite the possibility
that the immune responses mounted against malarial para-
sites by hosts who have experienced malarial attacks may be
different from those mounted by hosts lacking such experi-
ences.31 Second, some of these studies10,33 did not consider
possible differences between children and adults in terms of
their cytokine35 and febrile36 responses to malarial parasites.
Third, none of these studies considered the possibility of sex-
related differences in the host’s febrile responses in infec-
tions.27 It is also questionable whether the findings of these
studies, which were conducted in the tropical countries and
had study subjects selected from individuals living indig-
enously in these countries, will be valid in case of P. vivax
malaria, as seen in an indigenous population in a temperate
country such as Korea. Future prospective studies should ad-
dress this issue. This is important given the possibility of the
existence of tropical and temperate zone types of P. vivax.37
It is also believed that the adaptive properties of P. vivax in
different climatic conditions may have an effect on the clinical
expression of P. vivax malaria.38 Of note, Chai39 and Kim40
have already reported what they described as early and de-
layed onset type of P. vivax malaria in indigenous Korean
subjects. However, apart from the rapidity of the onset of
clinical disease and relapse,41 it is not known whether the
clinical expression of delayed onset P. vivax malaria differs
from those of the early onset-type disease. Unfortunately, we
could not address this issue in our study because unlike the
studies of Chai39 and Kim,40 we did not have a subgroup of
patients who had once lived in a malarious area and devel-
oped malaria at varying intervals only after they had left the
endemic area. At the time of admission, the subjects included
in our study had been resident in the DMZ for 12−14 months.
No patient included in this study was found to have had an
early- or delayed-onset type of P. vivax malaria when the
patient’s date of admission had been considered in conjunc-
tion42 with the patient’s duration of residency in the DMZ at
the time of admission and the season of peak transmission of
malaria. All patients denied having ever visited any geo-
graphic location outside Korea where malaria was known to
be endemic. Prior to admission, no patient included in this
study had ever been tested for evidence of infection by P.
vivax. This is not unexpected because active duty servicemen
in the DMZ are not routinely tested for malarial infection.
The possible effects of differences in the temporal expres-
sion of cytokines between the study subjects were considered.
No patient included in this study had a temperature subse-
quently recorded during the course of hospitalization that was
higher than that recorded on admission. All patients in the
non-hyperpyrexial group repeatedly denied having ever ex-
perienced sudden onset of chills and rigors followed by sharp
increases in temperature considered typical8 of the febrile
paroxysm of P. vivax malaria during the course of the current
illness that led them to seek medical attention. By their own
accounts, which may not be inaccurate,43 it was the persis-
tence of feverishness and body aches unassociated with any
apparent daily fluctuation in body temperature that prompted
them to seek medical attention. We believe, as do other in-
vestigators,44 that the pattern of febrile illness reported by
these patients on admission is not incompatible with P. vivax
malaria. Furthermore, although considered characteristic, a
considerable proportions of patients with P. vivax malaria do
not develop febrile paroxysm at any stage during the course
of their illness.29,30
In conclusion, male patients with P. vivax malaria who pre-
sented with hyperpyrexia had significantly higher serum con-
centrations of IL-6, IL-10, and IFN- compared with those
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without hyperpyrexia. The serum concentrations of TNF-
were not significantly different between those who presented
with hyperpyrexia and those who did not. Further studies are
needed to examine whether serum levels of these cytokines in
patients with P. vivax malaria also parallel their concentra-
tions at the tissue sites of their production and action.
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